ESR1 and breast cancer: Indeed, the E2 doses required to promote ER+ breast cancer growth in osteolytic xenograft models also increase murine bone mass[18,20,21,26,28,34] and furthermore, can induce osteolytic murine osteosarcomas in some animals, as previously demonstrated by our laboratory[34].